7,8-diaminopelargonic acid synthase (BioA) of Mycobacterium tuberculosis is a recently validated target for therapeutic intervention in the treatment of tuberculosis (TB). Using biophysical fragment screening and structural characterization of compounds, we have identified a potent aryl hydrazine inhibitor of BioA that reversibly modifies the pyridoxal-5’-phosphate (PLP) cofactor, forming a stable quinonoid. Analogous hydrazides also form covalent adducts that can be observed crystallographically but are incapable of inactivating the enzyme. In the X-ray crystal structures, small molecules induce unexpected conformational remodeling in the substrate binding site. We compare these conformational changes to those induced upon binding of the substrate (7-keto-8-aminopelargonic acid), and characterize the inhibition kinetics and the X-ray crystal structures of BioA with the hydrazine compound and analogs to unveil the mechanism of this reversible covalent modification.